(1R,8S)-8-Amino-4-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-7-ox o-2-thiabicyclo[4.2.0]oct-4-ene-5-carboxylate

We are (1R,8S)-8-Amino-4-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-7-ox o-2-thiabicyclo[4.2.0]oct-4-ene-5-carboxylate CAS:167271-60-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:
(1R,8S)-8-Amino-4-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-7-ox o-2-thiabicyclo[4.2.0]oct-4-ene-5-carboxylate
CAS.NO:167271-60-5
Synonyms:7-ACP
Imidazo[1,2-b]pyridazinium,1-[[(6R,7R)-7-amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-,inner salt
Molecular Formula:C15H14N4O3S
Molecular Weight:330.36166
 
Specification:
Appearance:Off-white to white powder
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:For the synthesis of Cefozopran

(1R,8S)-8-Amino-4-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-7-ox o-2-thiabicyclo[4.2.0]oct-4-ene-5-carboxylate


Related News: This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.Hept-6-enoic acid The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.(1R, 2R) -N, N'-Dimetil-1,2-ciclohexanodiamina CAS:68737-65-5 The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.875664-44-1 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.

Related Products
Product Name
(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoic acid View Details
2-PHENYLBUTYRONITRILE View Details
5-Bromo-2-fluorobenzaldehyde View Details
Diallylamine manufacturer O-tert-Butyl-L-serine methyl ester hydrochloride manufacturer 1-Bromo-2-methyl-4-nitrobenzene manufacturer Methyl 2-amino-4-((2,5-dichlorophenyl)carbamoyl)benzoate manufacturer 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone manufacturer